GPD1 inhibits the carcinogenesis of breast cancer through increasing PI3K/AKT-mediated lipid metabolism signaling pathway

Zhengchao Xia, Ningming Zhao, Mingzhou Liu, Dandan Jiang, Shanjun Gao, Peizhi Ma, Li HuangHeliyon 2023 · DOI

TL;DR

This study reveals that Glycerol 3-phosphate dehydrogenase 1 (GPD1) acts as a tumor suppressor in breast cancer by promoting lipid metabolism via the PI3K/AKT signaling pathway. The findings suggest GPD1 could serve as a valuable prognostic biomarker and therapeutic target for breast cancer patients.

What Problem Does This Paper Address?

Breast cancer remains a leading cause of cancer-related deaths in women, and while advancements in diagnosis and treatment have improved survival, prognosis for many patients has not dramatically improved. Aberrant cellular metabolism, particularly involving lipids, is increasingly recognized as a critical factor in cancer progression, influencing everything from tumor cell plasticity and drug resistance to metastasis. While GPD1 has been implicated as a tumor suppressor in various cancers, its specific role and the underlying mechanisms in breast cancer, especially concerning lipid metabolism and signaling pathways, remained largely unclear. This paper aims to elucidate these mechanisms and explore the clinical relevance of GPD1 in breast cancer.

Methods

The researchers employed a multi-faceted approach to investigate GPD1's role:

  • Cellular Assays: Standard techniques like CCK-8 (cell proliferation), wound healing (cell migration), and Transwell assays (cell invasion) were used to assess the functional impact of GPD1 overexpression in breast cancer cell lines (MCF-7 and MDA-MB-231).
  • Molecular Biology Techniques:
    • RT-qPCR and Western Blotting: Used to measure mRNA and protein expression levels of GPD1 and key signaling molecules (PI3K, AKT, GSK3β, PTEN) in both normal and cancer cells, and to confirm GPD1 overexpression.
  • Pharmacological Inhibition: LY294002, a known PI3K/AKT pathway inhibitor, was used to probe the dependency of GPD1's effects on this pathway.
  • Lipidomics: LC-ESI-MS/MS was employed to comprehensively analyze changes in lipid profiles (differential metabolites, DMs) in GPD1-overexpressing cells compared to controls. Pathway enrichment analysis (KEGG) was performed on these DMs.
  • Bioinformatic Analysis: Publicly available datasets from The Cancer Genome Atlas (TCGA) were analyzed using the UALCAN portal to assess GPD1 mRNA expression levels in different breast cancer subtypes and stages, and to correlate GPD1 expression with patient survival.

Datasets

  • Human Breast Cancer Cell Lines: MCF-7, MDA-MB-231 (cancerous), and MCF-10A (normal) were used.
  • Clinical Specimens: 50 paired breast cancer tumor tissues and adjacent normal tissues were collected from Henan Provincial People's Hospital.
  • The Cancer Genome Atlas (TCGA): Whole-transcriptome data and clinical characteristics of human breast cancer patients were acquired from TCGA via the UALCAN portal for bioinformatic analysis of GPD1 expression and survival.

Key Insights and Ideas

  • GPD1 as a Breast Cancer Suppressor: The study provides strong evidence that GPD1 actively inhibits key hallmarks of cancer progression: proliferation, migration, and invasion in breast cancer cells.
  • The PI3K/AKT-Lipid Metabolism Axis: A central finding is that GPD1's tumor-suppressive effects are mediated by activating the PI3K/AKT signaling pathway, which in turn promotes lipid synthesis. This highlights a critical crosstalk between a key oncogenic signaling pathway and cellular metabolism.
  • Metabolic Reprogramming: GPD1 overexpression leads to significant changes in the cellular lipidome, with an upregulation of various lipid classes, suggesting a metabolic shift towards lipid synthesis. This is further supported by the observed increase in key lipid metabolic genes.
  • Clinical Relevance of GPD1: The bioinformatic analysis reveals that GPD1 expression is significantly downregulated in breast cancer tissues compared to normal tissues and across different cancer stages and subtypes. Crucially, higher GPD1 expression is positively correlated with better survival rates in breast cancer patients, positioning it as a potential prognostic biomarker.

Key Results

  • Overexpression of GPD1 significantly inhibited proliferation, migration, and invasion in MCF-7 and MDA-MB-231 breast cancer cells.
  • GPD1 overexpression led to the activation of the PI3K/AKT signaling pathway, evidenced by increased phosphorylation of AKT and GSK3β.
  • Inhibition of the PI3K/AKT pathway with LY294002 attenuated the anti-proliferative effects of GPD1 overexpression.
  • Lipidomic analysis identified significant alterations in lipid metabolism, with an upregulation of various lipid classes, in GPD1-overexpressing cells.
  • TCGA data showed significantly lower GPD1 mRNA expression in breast cancer tissues compared to normal tissues.
  • Higher GPD1 expression was associated with improved overall survival in breast cancer patients, particularly in pre-menopausal women and the Luminal subtype.

Limitations and Future Work

  • In Vivo Validation: While the study provides strong in vitro and bioinformatic evidence, the authors acknowledge that further in vivo experiments are needed to fully validate these findings and understand the mechanisms.
  • Downstream Mechanisms: The precise downstream regulatory mechanisms by which GPD1 influences lipid metabolism and the PI3K/AKT pathway require further investigation.
  • Composite Biomarker Models: The authors suggest that combining GPD1 with other lipid metabolites could create more robust prognostic models, indicating a direction for future research in developing advanced diagnostic and prognostic tools.
  • Estrogen Correlation: The observed correlation between estrogen levels, menopausal status, and GPD1 expression warrants further in-depth study to clarify its clinical implications.

Summary updated

Abstract

Glycerol 3-phosphate dehydrogenase 1 (GPD1) acts as a tumor suppressor in various types of cancer. However, the mechanisms of GPD1 anti-tumor remain unclear in breast cancer. This study aims to explore the function and clinical relevance of GPD1 in breast cancer. We confirmed that GPD1 inhibited the ability of proliferation, migration, and invasion in GPD1 overexpression breast cancer cells by CCK-8, wound healing, and Transwell assays, respectively. We found that GPD1 overexpression activated the lipid synthesis pathway and PI3K/AKT signaling pathway. The inhibitory effect of GPD1 on breast cancer cells was also weakened after treatment with LY294002, a PI3K/AKT pathway inhibitor. These results indicated that GPD1 suppressed the carcinogenesis of breast cancer through increasing PI3K/AKT-mediated lipid signaling pathways. Meanwhile, we detected that the relationship between GPD1 level and survival rate presents a positive correlation in breast cancer patients from the Cancer Genome Atlas (TCGA) database. Therefore, GPD1 can be a prognostic biomarker and target in developing therapeutic strategies for breast cancer patients.
BibTeX
@inproceedings{xia2023gpd,
  author = {Zhengchao Xia and Ningming Zhao and Mingzhou Liu and Dandan Jiang and Shanjun Gao and Peizhi Ma and Li Huang},
  title = {{GPD1 inhibits the carcinogenesis of breast cancer through increasing PI3K/AKT-mediated lipid metabolism signaling pathway}},
  booktitle = {Heliyon},
  year = {2023},
  doi = {10.1016/j.heliyon.2023.e18128},
}
Figure